Skip to main content

Table 1 Clinical characteristics

From: Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes

  Overall BP-SES DP-EES p value
n = 141 n = 44 n = 100
Age, years 70 (62–77) 67 (57–78) 70 (64–77) 0.278
Male, n (%) 115 (81.6) 32 (72.7) 85 (85.0) 0.082
Body mass index 24.7 (22.0–27.1) 24.8 (22.4–26.7) 23.8 (22.4–26.7) 0.856
Follow-up duration, days 386 (334–472) 377 (308–435) 390 (347–484) 0.139
Risk factor, n (%)
 Hypertension 122 (86.5) 40 (90.9) 85 (85.0) 0.335
 Dyslipidemia 109 (77.3) 35 (79.6) 76 (76.0) 0.641
 Chronic kidney disease 87 (61.7) 25 (56.8) 64 (64.0) 0.414
 Hemodialysis 21 (14.9) 6 (13.6) 15 (15.0) 0.831
 Smoking 25 (17.9) 10 (22.7) 15 (15.2) 0.271
 Family history of IHD 36 (26.1) 14 (32.6) 23 (23.5) 0.259
 Previous myocardial infarction 42 (29.8) 9 (20.5) 35 (35.0) 0.081
 Previous PCI 59 (41.9) 15 (34.1) 47 (47.0) 0.150
 Previous CABG 5 (3.5) 3 (6.8) 2 (2.0) 0.146
Medication at PCI, n (%)
 Aspirin 125 (88.7) 37 (84.1) 90 (90.0) 0.311
 Thienopyridine 114 (80.9) 31 (70.5) 86 (86.0) 0.028
 Statin 116 (82.3) 36 (81.8) 83 (83.0) 0.863
 ACEI/ARB 109 (77.3) 30 (68.2) 81 (81.0) 0.092
 Beta blocker 93 (66.0) 22 (50.0) 74 (74.0) 0.005
 Calcium channel blocker 70 (49.6) 19 (43.2) 51 (51.0) 0.387
 Insulin 26 (18.6) 6 (14.0) 21 (21.0) 0.324
Laboratory findings
 Triglycerides, mg/dL 125 (92–185) 116 (91–176) 125 (92–197) 0.284
 LDL-C, mg/dL 85 (67–109) 90 (68–107) 80 (66–112) 0.700
 HDL-C, mg/dL 49 (41–58) 51 (42–66) 48 (40–57) 0.112
 HbA1c, % 6.8 (6.3–7.3) 6.8 (6.3–7.4) 6.8 (6.3–7.3) 0.907
 eGFR, mL/min/1.73 m2 52 (34–64) 55 (35–67) 51 (32–63) 0.253
 BNP, pg/mL 108 (46–322) 79 (27–299) 115 (54–350) 0.108
 Left ventricular ejection fraction, % 60 (50–65) 61 (51–66) 59 (50–65) 0.293
  1. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, BNP brain natriuretic peptide, BP-SES biodegradable polymer sirolimus-eluting stent, CABG coronary artery bypass graft, DP-EES durable polymer everolimus-eluting stent, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, HDL-C high density lipoprotein cholesterol, IHD ischemic heart disease, LDL-C low-density lipoprotein cholesterol, PCI percutaneous coronary intervention